Logo

American Heart Association

  2
  0


Final ID: Sa2176

Patient-Reported Health Status Among Patients with Heart Failure with Improved Ejection Fraction

Abstract Body (Do not enter title and authors here): Introduction
The prevalence of heart failure with improved ejection fraction (HFimpEF) is growing. The association of ejection fraction recovery and changes in health status has not been previously reported.

Hypothesis
We hypothesized patient-reported health status (HS) will be significantly better among patients with HFimpEF compared with those with HF with reduced ejection fraction (HFrEF) or HF with mid-range/preserved ejection fraction (HFmrEF/HFpEF).

Methods
We identified patients with HF with at least 2 encounters with the Stanford cardiology clinic who completed a routinely collected Kansas City Cardiomyopathy Questionnaire (KCCQ)-12 from 8/2020 to10/2023. HFimpEF was defined as most recent EF>40% from a preceding echocardiogram > 30 days prior with EF<40%. We compared patient sociodemographic and clinical characteristics across EF classifications. We analyzed KCCQ-12 Overall Summary Score (OSS) across EF classifications with and without adjustment for patient characteristics via multivariable linear regression, from which we calculated the R2 to determine the impact of clinical characteristics on variation in HS among patients with HFimpEF.

Results/Data
A total of 2,519 patients were included in this analysis, of which 18.7% had HFimpEF, 55.7% had HFmrEF/HFpEF, and 25.6% had HFrEF. Median KCCQ-12 OSS was 80.3, 73.9, and 80.8 for HFimpEF, HFrEF and HFmr/HFpEF patients, respectively. Patients with HFimpEF were less likely to be women compared with patients with HFmrEF/HFpEF (41% vs 58%, p<0.01). There was substantial overlap in the KCCQ-12 OSS across EF classifications (Figure). KCCQ-12 OSS score was 5.2 points lower among patients with HFrEF compared with patients with HFimpEF [(95% CI: -8.2 to -2.3); p=0.01] but patients with HFimpEF had similar scores to those with HFmrEF/HFpEF [-1.1 (95% CI: -3.7 to 1.6); p=0.43]. Among patients with HFimpEF, a multivariable regression model explained 16% of the variation in the KCCQ-12 OSS.

Conclusions
Despite improvement in EF, patients with HFimpEF continue to have impaired HS that is similar to patients with HFpEF and HFmrEF. Further research is needed to better understand impaired HS and to identify interventions to improve health status among patients with HFimpEF.
  • Vasti, Elena  ( Stanford Health Care , Stanford , California , United States )
  • Zheng, Jimmy  ( Stanford Health Care , Stanford , California , United States )
  • Kalwani, Neil  ( VA Palo Alto Health Care System , Palo Alto , California , United States )
  • Dejong, Colette  ( UCSF , San Francisco , California , United States )
  • Bhatt, Ankeet  ( Kaiser Permenante , San Francisco , California , United States )
  • Ambrosy, Andrew  ( Kaiser Permanente , San Francisco , California , United States )
  • Din, Natasha  ( Stanford University, VAPAHCS , Palo Alto , California , United States )
  • Heidenreich, Paul  ( Stanford University , Stanford , California , United States )
  • Sandhu, Alexander  ( Stanford University , Stanford , California , United States )
  • Author Disclosures:
    Elena Vasti: DO NOT have relevant financial relationships | Jimmy Zheng: DO NOT have relevant financial relationships | Neil Kalwani: DO NOT have relevant financial relationships | Colette Dejong: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):iRhythm Technologies: spouse is employed by and owns stock:Active (exists now) | Ankeet Bhatt: DO have relevant financial relationships ; Consultant:Novo Nordisk:Past (completed) ; Consultant:Merck:Past (completed) | Andrew Ambrosy: DO have relevant financial relationships ; Consultant:Merck:Active (exists now) ; Consultant:sc Pharma:Past (completed) | Natasha Din: DO NOT have relevant financial relationships | Paul Heidenreich: DO NOT have relevant financial relationships | Alexander Sandhu: DO have relevant financial relationships ; Consultant:Acumen LLC:Past (completed) ; Consultant:Lexicon Pharmaceuticals:Past (completed) ; Research Funding (PI or named investigator):Novartis Pharmaceuticals:Active (exists now) ; Research Funding (PI or named investigator):Reprieve Cardiovascular :Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Heart Failure: Psychosocial, Frailty and Other Factors

Saturday, 11/16/2024 , 02:00PM - 03:00PM

Abstract Poster Session

More abstracts on this topic:
Early supported discharge program decreases length of hospital stay and demonstrates high clinic follow-up rates after stroke

Tenberg Amelia, Zink Elizabeth, Bahouth Mona

Barriers and Facilitators to Outpatient Cardiac Rehabilitation Attendance Among Patients with Low Socioeconomic Status: A Qualitative Study

Mathews Lena, Okonkwo Miriam Chiamaka, Tolefree Tionna, Stewart Kerry, Benz Scott Lisa, Cooper Lisa, Ndumele Chiadi, Matsushita Kunihiro, Riekert Kristin

More abstracts from these authors:
Variation in Prevalence, Treatment, and Outcomes in Heart Failure with Improved Ejection Fraction by Race and Ethnicity

Chang Alex, Vasti Elena, Sandhu Alexander, Go Alan, Adatya Sirtaz, Bhatt Ankeet, Lee Keane, Parikh Rishi, Ambrosy Andrew, Tan Thida, Hamilton Steven, Pabon Porras Maria, Vardeny Orly, Ku Ivy

Prevalence, Clinical Characteristics, and Outcomes in Heart Failure with Improved Ejection Fraction by Chronological Age

Srikanth Kishan, Vasti Elena, Sandhu Alexander, Go Alan, Adatya Sirtaz, Bhatt Ankeet, Lee Keane, Parikh Rishi, Ambrosy Andrew, Tan Thida, Hamilton Steven, Vardeny Orly, Krishnaswami Ashok, Ku Ivy

You have to be authorized to contact abstract author. Please, Login
Not Available